SCHEMBL24252866

SCHEMBL24252866

COc1cc(C#N)c(Cl)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.43
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC22A12 Q96S37 1/20 0.39
MAOB P27338 1/20 0.38
FASN P49327 1/20 0.38
PGR P06401 2/20 0.37
GPR35 Q9HC97 1/20 0.37
HPGD P15428 1/20 0.37
IMPDH2 P12268 1/20 0.37
IMPDH1 P20839 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129737 0.93 KDM4E (0.41) SRCKDM4EUSP2ALDH1A1SLC22A12
SCHEMBL20241856 0.85 SRC (0.49) SRCKDM4EUSP2ALDH1A1HPGD
SCHEMBL2473900 0.79 GAA (0.45) SRCKDM4EUSP2ALDH1A1SLC22A12
SCHEMBL28902119 0.78 POLB (0.52) KDM4EUSP2ALDH1A1IMPDH2IMPDH1
SCHEMBL15797427 0.78 GAA (0.60) SRCKDM4EUSP2ALDH1A1SLC22A12
SCHEMBL23663416 0.78 PGR (0.46) KDM4EUSP2ALDH1A1PGRIMPDH2
SCHEMBL31510972 0.78 TRPV4 (0.41) KDM4EUSP2ALDH1A1PGRIMPDH2
SCHEMBL29663687 0.78 GRIN2D (0.45) ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL21404002 0.78 GRIN2D (0.45) ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7980232 0.76 KDM4E (0.46) KDM4EUSP2ALDH1A1MAOBIMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SRC 4281/4885KDM4E 3923/4885USP2 4226/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SRC 4281/4885KDM4E 3923/4885USP2 4226/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SRC 4281/4885KDM4E 3923/4885USP2 4226/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SRC 3857/4885KDM4E 2913/4885USP2 2397/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SRC 1938/4885KDM4E 4178/4885USP2 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.